29 completed, 10 unknown, 9 recruiting, 5 terminated. 20 Phase 2, 10 Phase 3, 9 Phase 1, 5 Not applicable, 2 Phase 4.
Follow Congenital Adrenal Hyperplasia: new trials by email Literature Review of Congenital Adrenal Hyperplasia trials Research Report on Congenital Adrenal Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia exposure to healthcare transition protocol - Congenital Adrenal Hyperplasia | Not yet recruiting | University of Alabama at Birmingham | 40 | 2027-01-01 | 2026-10-14 | |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) NBIP-01435 - Congenital Adrenal Hyperplasia | Phase 2 | Not yet recruiting | Neurocrine Biosciences | 36 | 2026-12-01 | 2026-09-30 |
| Evaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia, Adrenal Insufficiency | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-09-01 | 2026-07-21 | |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Recruiting | Neurocrine Switzerland GmbH | 20 | 2026-07-01 | 2026-09-16 |
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 / Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 153 | 2026-01-22 | 2026-11-10 |
| A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-12-11 | 2026-11-10 |
| A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia virtual educational based transition intervention self-paced - Congenital Adrenal Hyperplasia | Not applicable | Withdrawn | National Institutes of Health Clinical Center (CC) | 2025-12-09 | 2025-12-10 | |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Active not recruiting | Neurocrine Switzerland GmbH | 7 | 2025-09-30 | 2026-08-28 |
| An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia atumelnant (CRN04894) - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 | Recruiting | Crinetics Pharmaceuticals Inc. | 200 | 2025-02-25 | 2026-06-29 |
| Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency Cytochrome P450 Oxidoreductase Deficiency, Hypertension | Completed | Ozge Bayrak Demirel | 51 | 2024-12-24 | 2025-09-08 | |
| Growing up With the Young Endocrine Support System (YESS!) YESS! game, Snake '97, Transition-toolkit - Congenital Adrenal Hyperplasia, Hypogonadotropic Hypogonadism | Not applicable | Not yet recruiting | dr. Laura C. G. de Graaff-Herder | 160 | 2024-12-01 | 2023-09-07 |
| Testicular Adrenal Rest Tumor in Congenital Adrenal Hyperplasia Patients Attending Assuit University Children Hospital Testicular Adrenal Rest Tumor, Congenital Adrenal Hyperplasia | Unknown | Assiut University | 30 | 2024-10-01 | 2024-08-21 | |
| Institutional Registry of Rare Diseases Rare Diseases, Amyloidosis | Recruiting | Hospital Italiano de Buenos Aires | 380 | 2024-07-01 | 2026-01-14 | |
| Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH Congenital Adrenal Hyperplasia, Exercise Capacity | Completed | Hacettepe University | 48 | 2024-02-22 | 2025-07-08 | |
| Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) atumelnant (CRN04894) - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 38 | 2023-07-03 | 2026-09-10 |
| Androgen Reduction in Congenital Adrenal Hyperplasia Abiraterone acetate, Placebo, Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2023-01-01 | 2023-02-01 | |
| A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia Lu AG13909 - Congenital Adrenal Hyperplasia | Phase 1 / Phase 2 | Recruiting | H. Lundbeck A/S | 42 | 2022-12-19 | 2026-03-09 |
| Baby Detect : Genomic Newborn Screening Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 | Completed | Centre Hospitalier Universitaire de Liege | 6824 | 2022-09-01 | 2025-08-12 | |
| Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency Congenital Adrenal Hyperplasia | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 30 | 2022-06-24 | 2024-12-31 | |
| Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia Chronocort, Cortef, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 55 | 2022-05-24 | 2026-10-02 |
Showing 20 of 66. Sign in to see all of them.
Adrenal Hyperplasia, Congenital (66) · Adrenal Insufficiency (7) · Disorders of Sex Development (7) · Adrenal Gland Diseases (5) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (5) · Cushing Syndrome (3) · Ovotesticular Disorders of Sex Development (3) · Adrenocortical Hyperfunction (2) · Adrenogenital Syndrome (2) · Combined Pituitary Hormone Deficiency (2) · Dwarfism, Pituitary (2) · Endocrine System Diseases (2) · Gaucher Disease (2) · Genetic Diseases, Inborn (2) · Hepatolenticular Degeneration (2)
Female Urogenital Diseases (66) · Female Urogenital Diseases and Pregnancy Complications (66) · Male Urogenital Diseases (66) · Nutritional and Metabolic Diseases (66) · Urogenital Diseases (66) · Congenital Abnormalities (65) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (65) · Gonadal Disorders (65) · Metabolic Diseases (65) · Adrenogenital Syndrome (64) · Endocrine System Diseases (64) · Genetic Diseases, Inborn (64) · Metabolism, Inborn Errors (64) · Steroid Metabolism, Inborn Errors (64) · Urogenital Abnormalities (64)
Hydrocortisone (8) · Dexamethasone (4) · Prednisone (4) · crinecerfont (4) · Prednisolone (3) · Abiraterone Acetate (2) · Interviews as Topic (2) · Blood Specimen Collection (1) · Cortisone (1) · Exercise (1) · Fludrocortisone (1) · N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (1) · NBI 77860 (1) · Nifedipine (1) · Pioglitazone (1)
Neurocrine UK Limited (8) · Spruce Biosciences (5) · Crinetics Pharmaceuticals Inc. (4) · Neurocrine Biosciences (4) · Adrenas Therapeutics Inc (2) · Ain Shams University (2) · Assistance Publique - Hôpitaux de Paris (2) · Assiut University (2) · Hospices Civils de Lyon (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Neurocrine Switzerland GmbH (2) · Shanghai Jiao Tong University School of Medicine (2) · University of Texas Southwestern Medical Center (2) · dr. Laura C. G. de Graaff-Herder (2) · Centre Hospitalier Universitaire de Liege (1)
United States (34) · France (13) · Italy (12) · United Kingdom (12) · Germany (9) · Brazil (7) · Netherlands (7) · Poland (7) · Sweden (7) · Spain (6) · Argentina (5) · Belgium (5) · Canada (5) · Australia (4) · Turkey (Türkiye) (4)
Perrin C White, MD (2) · Adrian Gadano, MD (1) · Alessandra Gambineri, MD (1) · Anne Bachelot, MD, PhD (1) · Arpana G Inman (1) · Catherine Cornu, MD (1) · Christy Foster, MD (1) · Cornelis J Tack, MD, PhD (1) · D Merke (1) · David E Sandberg, PhD (1) · Debbie Merke, MD (1)
PMID 33527139, PMID 34146101, PMID 20719839, PMID 23337727, PMID 24878054, PMID 25494662, PMID 32589738, PMID 33278125, PMID 35283460, PMID 37343084, PMID 38828945, PMID 38828955
2023 (3), 2019 (1), M01RR001070 (1), R01HD057930 (1), U01HD083493 (1)